Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

First Posted Date: 2004-03-08

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Target Recruit Count: 462

Registration Number: NCT00078611

Locations: 🇺🇸
Morowitz, Marion, Laessing, Shocket, Bashir, Steinberg, Salcedo, Washington, District of Columbia, United States
🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

and more 72 locations

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2003-04-01

Last Posted Date: 2006-09-12

Lead Sponsor: Biogen

Target Recruit Count: 400

Registration Number: NCT00057343

Locations: 🇺🇸
Research Site, Wausau, Wisconsin, United States
🇺🇸
Biogen Idec Incorporated, San Diego, California, United States

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

First Posted Date: 2003-03-06

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Target Recruit Count: 60

Registration Number: NCT00055536

Locations: 🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸
Memphis Gastroenterology Group, Memphis, Tennessee, United States

and more 15 locations

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

First Posted Date: 2003-02-28

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Target Recruit Count: 30

Registration Number: NCT00055367

Locations: 🇺🇸
The Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 10 locations

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: IDEC-114

First Posted Date: 2002-11-05

Last Posted Date: 2013-09-16

Lead Sponsor: Biogen

Target Recruit Count: 90

Registration Number: NCT00048555

Locations: 🇺🇸
Research site, Charlottesville, Virginia, United States

Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2002-10-02

Last Posted Date: 2013-09-16

Lead Sponsor: Biogen

Target Recruit Count: 70

Registration Number: NCT00046488

Locations: 🇺🇸
Research Site, Houston, Texas, United States

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

First Posted Date: 2002-04-04

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Registration Number: NCT00032786

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

First Posted Date: 2002-04-04

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Target Recruit Count: 905

Registration Number: NCT00032799

Locations: 🇺🇸
Elan Pharmaceuticals, San Diego, California, United States

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

Phase 1

Completed

Conditions: Gliosarcoma
Oligoastrocytoma, Mixed
Glioblastoma Multiforme
Anaplastic Astrocytoma

First Posted Date: 2002-02-22

Last Posted Date: 2020-11-17

Lead Sponsor: Biogen

Target Recruit Count: 12

Registration Number: NCT00031083

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 2 locations

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Natalizumab
Drug: Placebo

First Posted Date: 2002-02-18

Last Posted Date: 2009-06-18

Lead Sponsor: Biogen

Target Recruit Count: 1200

Registration Number: NCT00030966

Locations: 🇺🇸
Mercy Hospital Outpatient Pharmacy, Des Moines, Iowa, United States
🇺🇸
University of Pittsburgh, Department of Neurology, Pittsburgh, Pennsylvania, United States
🇩🇪
Asklepios Klinik Schildautal, Seesen/Harz, Germany

and more 84 locations

Home Terms & Conditions Privacy Policy